| Autor: |
Caroti KS; School of Pharmacy, University of Connecticut, West Suffield, Connecticut, USA.; Evidence-Based Practice Center, Hartford Hospital, Hartford, Connecticut, USA., Khorana AA; Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio, USA., Becattini C; Department of Internal and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy., Lee AYY; Division of Hematology-Department of Medicine, University of British Columbia and BC Cancer, Vancouver, Canada., Ekbom A; Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden., Carrier M; Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Canada., Cohen AT; Department of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK., Brescia C; Freshtech IT, LLC, East Hartford, Connecticut, USA., Abdelgawwad K; Bayer AG, Berlin, Germany., Psaroudakis G; Bayer AG, Berlin, Germany., Rivera M; Bayer AG, Berlin, Germany., Schaefer B; Bayer AG, Berlin, Germany., Brobert G; Bayer AG, Berlin, Germany., Coleman CI; School of Pharmacy, University of Connecticut, West Suffield, Connecticut, USA.; Evidence-Based Practice Center, Hartford Hospital, Hartford, Connecticut, USA. |
| Abstrakt: |
Cancer-associated venous thromboembolism (CAT) guidelines recommend direct oral anticoagulants as alternatives to low-molecular-weight heparin (LMWH) in most patients. This study compared the effectiveness and safety of rivaroxaban versus LMWH for a broad CAT cohort. The cohort study used electronic health data from January 2012 to December 2020 to evaluate patients with active cancer experiencing acute venous thromboembolism (VTE) and treated with rivaroxaban or LMWH. Propensity score-overlap weighted hazard ratios (HRs) and 95% confidence intervals (CIs) for VTE, bleeding-related hospitalization, and all-cause mortality were calculated. In total, 4935 patients were identified (27.9% on rivaroxaban and 72.1% on LMWH). The cancer types included gastrointestinal (29.4%), genitourinary (26.2%), lung (24.0%), breast (19.7%), and hematologic (14.4%). Rivaroxaban was associated with a reduction in recurrent VTE versus LMWH among all patients with cancer (HR = 0.78; 95%CI = 0.61-0.99) at 3 months. No differences in bleeding-related hospitalization or all-cause mortality were observed. Directionally similar results to those at 3 months were observed at 6 months for all outcomes. In conclusion, we observed fewer recurrent VTE cases and no increase in bleeding-related hospitalizations with rivaroxaban versus LMWH at 3 months in this patient cohort with various cancer types. |
